Athero Review - Issue 1/2024

Editorial

Guidelines

Consensus statement of the European Atherosclerosis Society on the 2022 lipoprotein(a) – responses to the frequently asked questions about these recommendations

Lukáš Zlatohlávek, Vladimír Bláha, Renata Cífková, Tomáš Freiberger, David Karásek, Pavel Kraml, Jan Piťha, Hana Rosolová, Vladimír Soška, Tomáš Štulc, Michal Vrablík Za Výbor Čsat, Jana Mašková

Reviews

PCSK9 inhibitors (temporarily) in the broad practice of outpatient specialists: short but positive experience

Michal Vrablík

First clinical experience with inclisiran in Slovakia – experience with administration, management and efficacy from one center

Štefan Tóth, Patrik Buček, Richard David, Matej Šajty

News from pre-specified subgroup analyzes of the CLEAR-Outcomes trial

Ubomíra Fábryová

I am 55 years old, my cholesterol is 6.5 mmol/l and I do not want statin

Jan Piťha, Michal Vrablík

Personal News

Professor Hana Rosolová jubilating

Semaglutide confirms its position in cardiovascular prevention in the SELECT study

Michal Vrablík

From International Literature

Research on remarkable articles from international literature

Eva Tůmová

Athero Review

2024 Issue 1